<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>phase III randomized-controlled study &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/phase-iii-randomized-controlled-study/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 28 Oct 2025 12:48:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>phase III randomized-controlled study &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>PReCedeNT Trial: PRRT Plus Chemo Boosts GEP-NETs</title>
		<link>https://bioengineer.org/precedent-trial-prrt-plus-chemo-boosts-gep-nets/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 28 Oct 2025 12:47:58 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAPE-TEM chemotherapy]]></category>
		<category><![CDATA[FDG-avid GEP-NETs]]></category>
		<category><![CDATA[Lutetium-177 DOTATATE PRRT]]></category>
		<category><![CDATA[phase III randomized-controlled study]]></category>
		<category><![CDATA[PReCedeNT trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/precedent-trial-prrt-plus-chemo-boosts-gep-nets/</guid>

					<description><![CDATA[In a groundbreaking initiative poised to reshape the therapeutic landscape for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), researchers have launched the PReCedeNT trial—a phase III randomized-controlled study investigating the synergy of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) combined with chemotherapy. This ambitious trial targets a particularly elusive and aggressive subset of GEP-NETs characterized by FDG-avidity, a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287705</post-id>	</item>
	</channel>
</rss>
